CROs & CMOs

Contract research organisations (CROs) and contract manufacturing organisations (CMOs) are among the strongest growth sectors of the pharmaceutical industry, with many firms experiencing double-digit annual growth. We work with CROs and CMOs in organisation asset restructuring and building core divisions through M&A activity.

Our team has a strong track-record having advised on some of the most important deals in the space including INC Research on its merger with inVentiv, GHO Capital on its acquisition of Sterling Pharma and Linguamatics on its acquisition by IQVIA.

A combination of our deep sector knowledge and long-standing industry relationships enables us to get the best outcomes for our clients.

CROs & CMOs Deals

Jun 2022
A Kester Capital-backed company
has received investment from
Jun 2022
has been acquired by
A company backed by GTCR and The Carlyle Group
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Jun 2021
has acquired a drug product manufacturing facility from
May 2021
has been acquired by
a Behrman Capital-backed company
Feb 2021
has been acquired by
Jan 2021
has invested in

Latest Insights

Insights
28th March 2022

The growing impact of Environmental, Social, and Governance (“ESG”) on pharmaceutical supply chains.

The Russian invasion of Ukraine has been touted as the final nail in the coffin of globalisation, confirming the nationalisation of key industries and products. With respect to pharmaceutical manufacturing, this is accelerating a trend which has been ongoing for 10 years, the repatriation of drug manufacturing from Asia to the US and Europe has […]

Reports
23rd February 2022

CRO Sector – M&A drivers and market trends – Q1 2022

Whilst the pandemic has caused unprecedented disruption on research and clinical trials, it has also launched the clinical trial landscape into a new area, one with the enhanced utilisation of decentralised trials and the long-awaited embracement of digital technologies to deliver improved patient care, reduced clinical trial costs and speedier outcomes. We have also seen […]

Insights
23rd February 2022

Discovery CROs: what is the “balanced business model” and how is this valued?

Discovery Contract Research Organisations (“CROs”) essentially provide lab-based discovery services such as medicinal chemistry, biological screening etc to pharma companies and biotech, and this business segment has exploded in size, sophistication and value in recent years and is now a focus of both M&A and PE investment. This is covered in our forthcoming white paper […]